Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165723 | 1.00 | CTSK (0.49) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL5169153 | 1.00 | CTSK (0.49) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL4489074 | 1.00 | CTSK (0.49) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL4492874 | 1.00 | CTSK (0.49) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL4483853 | 1.00 | CTSK (0.49) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL6230798 | 1.00 | CTSK (0.49) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL22128279 | 0.89 | CTSK (0.48) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL22128241 | 0.89 | CTSK (0.48) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL22128240 | 0.89 | CTSK (0.48) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL4861261 | 0.88 | CTSK (0.47) | CTSKCTSLCTSBCTSSCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517879-B2 | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-14 | — | — | US | disclosed |
| EP-1567489-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| CN-100378098-C | Crystalline derivatives of 2- (5-chlorothien-2-yl) -N- { (3S) -1- [ (1S) -1-methyl-2-morpholin-4-yl-2-oxoethyl ] -2-oxopyrrolidin-3-yl } ethenesulfonamide | GLAXO GROUP LTD (GB) | 2008-04-02 | — | — | CN | disclosed |
| US-7326785-B2 | Pyrrolidine derivatives as factor XA inhibitors | GLAXO GROUP LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| EP-1839659-A2 | Chemicals compounds | GLAXO GROUP LIMITED (GB) | 2007-10-03 | — | — | EP | disclosed |
| EP-1567519-B1 | CRYSTALLINE DERIVATIVES OF 2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL)ETHENSULFONAMIDE | GLAXO GROUP LTD (GB) | 2007-09-19 | — | — | EP | disclosed |
| US-20070142374-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | CHAN CHUEN | 2007-06-21 | — | — | US | disclosed |
| US-20070142375-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | CHAN CHUEN | 2007-06-21 | — | — | US | disclosed |
| US-7226929-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1395606-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LTD (GB) | 2007-05-02 | — | — | EP | disclosed |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
| US-20060160885-A1 | drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
| CN-1256324-C | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LTD (GB) | 2006-05-17 | — | — | CN | disclosed |
| CN-1745079-A | Crystalline derivatives of 2-(5-chlorothien-2-yl)-n-((3s)-1((1s)-1-methyl-2-morpholin-4-yl)-2-oxoethyl)-2-oxopyrrolidin-3-yl)ethensulfonamide | GLAXO GROUP LTD (GB) | 2006-03-08 | — | — | CN | disclosed |
| EP-1395553-B1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LTD (GB) | 2005-02-16 | — | — | EP | disclosed |
| CN-1538955-A | Pyrrolidine derivatives as factor Xa inhibitors | — | 2004-10-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160885-A1 | drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents | SERPINC1, F11, TFPI | CTSK 939/4885CTSL 787/4885CTSB 1981/4885 |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | TFPI, TFPI2, SERPINC1 | CTSK 260/4885CTSL 181/4885CTSB 238/4885 |
| US-20070142374-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F2, SERPINC1 | CTSK 380/4885CTSL 267/4885CTSB 291/4885 |
| US-20070142375-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F2, SERPINC1 | CTSK 380/4885CTSL 267/4885CTSB 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.